Pixatimod is under clinical development by Zucero Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pixatimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Pixatimod in Metastatic Melanoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pixatimod overview

Pixatimod (PG-545) is under development for the treatment of advanced solid tumors including microsatelite stable metastatic colorectal cancer, non-small cell lung cancer, metastatic colorectal cancer and metastatic melanoma, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, dengue and coronavirus disease 2019. It is administered through intravenous and subcutaneous (as a lyophilized powder) routes. It is a small molecule heparin sulfate mimetic. The drug candidate acts by targeting heparanase enzyme, VEGF, FGF-1, FGF-2, and TLR9 (toll-like receptor 9). It was also under development for the treatment of solid tumors (subcutaneous route).

Zucero Therapeutics overview

Zucero Therapeutics formerly Zucero Therapeutics Pty Ltd is a biotechnology company, which strives to discover and develop modified sugar compounds for the treatment of cancer. Its pipeline product candidate, PG545 (pixatimod, pINN), a new immunomodulatory agent, stimulates myeloid cells (M1 macrophages and dendritic cells (DC)). Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas. Next, it blocks tumour-associated macrophages (TAMs), in mouse models, which causes the inhibition of heparanase. PG545 completed a phase Ia clinical trial as a monotherapy in solid tumors and other inflammatory conditions. The company has research office in Darra, Queensland, Australia. Zucero Therapeutics is headquartered in Geelong, Victoria, Australia.

For a complete picture of Pixatimod’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.